Pain measurements and side effect profile of the novel cannabinoid ajulemic acid
- 30 June 2005
- journal article
- research article
- Published by Elsevier BV in Neuropharmacology
- Vol. 48 (8), 1164-1171
- https://doi.org/10.1016/j.neuropharm.2005.02.010
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Ajulemic acid: A novel cannabinoid produces analgesia without a “high”Life Sciences, 2004
- EFNS guidelines on neuropathic pain assessmentEuropean Journal of Neurology, 2004
- Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain, 2001
- Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic reviewBMJ, 2001
- Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic Neuralgia: A Quantitative Systematic ReviewJournal of Pain and Symptom Management, 2000
- Ajulemic Acid (CT3) A Potent Analog of the Acid Metabolites of THCCurrent Pharmaceutical Design, 2000
- Neuropathic pain: new insights, new interventions.Hospital Practice, 1998
- Analgesic effects of 1′,1′ dimethylheptyl-Δ8-THC-11-oic acid (CT3) in miceLife Sciences, 1998
- Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activitiesJournal of Medicinal Chemistry, 1992
- ‘Hangover’ effects the morning after marijuana smokingDrug and Alcohol Dependence, 1985